Skip to main content
Protagenic Therapeutics, Inc.\new logo

Protagenic Therapeutics, Inc.\new — Investor Relations & Filings

Ticker · PTIX ISIN · US74365N2027 LEI · 549300KPBYAVJLPDKB70 US Professional, scientific and technical activities
Open in API
Filings indexed 678 across all filing types
Latest filing 2024-03-30 Director's Dealing
Country US United States of America
Listing US PTIX

About Protagenic Therapeutics, Inc.\new

https://protagenic.com/

Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide-based therapeutics for stress-related disorders. The company's core technology is its TCAP (teneurin C-terminal associated peptide) platform, which utilizes neuropeptides to regulate the brain's stress response at a cellular level. This approach aims to counteract the 'Stress Feedback Loop' implicated in various neuropsychiatric and neurodegenerative conditions. Its lead drug candidate, PT00114, a synthetic TCAP, is being developed as a potential first-in-class treatment for disorders such as anxiety and depression.

Recent filings

Filing Released Lang Actions
Director's Dealing 2024
Director's Dealing
2024-03-30 English
Director's Dealing 2024
Director's Dealing
2024-03-30 English
Director's Dealing 2024
Director's Dealing
2024-03-30 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes references to Nasdaq deficiency notice resolution and compliance with listing rules, which are typical disclosures in an 8-K. The document is relatively short (4313 characters) and includes a press release as an exhibit. It does not contain detailed financial statements or comprehensive financial analysis, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a certification or officer attestation document, so it is not Regulatory Filings (RNS). The content is about a regulatory compliance event and announcement of resolution of a deficiency notice, which fits best under Regulatory Filings (RNS) as a general regulatory announcement. Therefore, the classification is RNS with high confidence.
2024-03-21 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-14 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 13, 2023, by Protagenic Therapeutics, Inc. It reports the results of the 2023 Annual Meeting of Stockholders, including voting outcomes on director elections and ratification of the independent auditor. The content focuses on the submission of matters to a vote of security holders and the official voting results. The document is relatively short (4446 characters) and contains detailed voting results, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). It is not an Annual Report, Audit Report, or Management Report, nor is it a simple announcement of a report publication. Therefore, the correct classification is DVA with high confidence.
2023-12-15 English

Browse filings by year

30 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.